Navigation Links
Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
Date:6/8/2009

PRINCETON, N.J., June 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that new clinical and preclinical data demonstrating the extended therapeutic bioavailability and tumor cell selectivity of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in leukemia were presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany, June 4-7, 2009 (Abstracts 1398 and 383).

"These findings underscore the potential pharmacological and pharmacokinetic advantages of CPX-351 in the treatment of advanced leukemias," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "Our nano-scale liposomal encapsulation maintains the desired 5:1 molar ratio of cytarabine:daunorubicin in CPX-351, extends bioavailability beyond that seen with conventional administration of the combination, and, based on this evidence, facilitates selectivity for and uptake by leukemia cells. As a result, CPX-351 may lengthen or enhance the anti-tumor activity of cytarabine:daunorubicin, even in patients with relapsed and refractory disease."

The first poster presented data on the pharmacokinetics and pharmacology of CPX-351 from a Phase I study of patients with relapsed or refractory acute leukemias.(1) Evidence of antitumor effect, details of which were presented at the American Society of Hematology (ASH) meeting in late 2008, included complete remissions (CRs) in 1 of 3 patients with ALL and 10 of 44 patients with AML (9 CRs and 1 CRp - complete remission without full platelet recovery). Some of these remissions occurred at dose levels as low as one-third to one-half of the maximum tolerated dose (MTD; established in this study as 101 u/m(2)). Treatment with CPX-351 was generally well tolerated, with cytopenia-related adverse events consistent with standard cytarabine:daunorubicin regimens. Alopecia and grade greater than or equal to 3 gastrointestinal adverse events were uncommon.

The
'/>"/>

SOURCE Celator Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
2. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
3. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
4. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
5. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
6. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
9. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
(Date:8/28/2014)... BELLINGHAM, Washington, USA (PRWEB) August 27, 2014 ... Colorado next month for SPIE Laser Damage 2014 ... on optical materials for high-power lasers will run 14-17 ... international society for optics and photonics . , The ... key for understanding laser damage to optical materials will ...
(Date:8/28/2014)... 2014 Supplementing their complete line ... for Eppendorf Safe Lock Centrifuge Tubes . ... highest quality tubes at an affordable price. Eppendorf ... doing chemical, medical, pharmaceutical, and life science research ... regularly able to afford Eppendorf products. , Eppendorf ...
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a ... and genetic deficiencies that result in metabolic disorders, announced ... Form S-1 with the U.S. Securities and Exchange Commission ... shares of its common stock. The number of shares ... offering have not yet been determined. Citigroup ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... MSC Care Management, the industry,s leading provider of ... workers, compensation claimants nationwide, announced today that it ... also focused on the workers, compensation industry, to ... management solution, known as S3. Integrated Healthcare Services, ...
... BETHESDA, Md., Oct. 4, 2011 Northwest Biotherapeutics ... will be presenting at the second annual Cancer ... 6, at the New York Academy of Medicine ... key opinion leaders, industry executives, and other stakeholders ...
... Oct. 4, 2011 Kylin Therapeutics, Inc., a ... has received a notice of allowance from United ... second U.S. patent application. This newly allowed patent ... as expanded areas on Kylin,s proprietary nanoparticle technology ...
Cached Biology Technology:MSC to Offer Surgical Implant Cost Management Solution through Acquisition of Integrated Healthcare Services 2NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 2NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 3NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 4Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology 2
(Date:8/28/2014)... is pleased to announce the selection of Dr. Fred ... Membership acknowledges those who have served ESA for at ... of the Society that has reached an extraordinary level. ... Governing Board and then voted on by the ESA ... Ceremony at Entomology 2014, ESA,s Annual Meeting in Portland, ...
(Date:8/28/2014)... Research Careers) Program has announced the travel award recipients ... 18 22, 2014 in San Diego, California. ... students, post doctorates and scientists from underrepresented groups into ... encourage the participation of young scientists at the American ... 16 awards totaling $29,600., The FASEB MARC Program is ...
(Date:8/28/2014)... on-off switch for Streptomyces , a group of ... world,s naturally derived antibiotic medicines. , Their hope ... to manipulate this switch to make nature,s antibiotic factory ... in Cell , found that a unique interaction ... protein called BldD ultimately controls whether a bacterium spends ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... belief that specific dietary changes can improve the symptoms of ... University of Rochester study, which found that eliminating gluten and ... impact on their behavior, sleep or bowel patterns. ... to date. The researchers took on the difficult yet crucial ...
... May 18, NASA,s Aqua satellite swept over the Gulf of ... the Moderate Resolution Imaging Spectroradiometer instrument captured sunglints in a ... three bright areas of sunglint within the area of the ... sun off the water,s surface. In calm waters, the rounded ...
... you know what is in your drinking water? A study ... thinking twice the next time you fill up that glass ... sciences professor in the College of Arts and Sciences, sampled ... concentrations of viruses and bacteria linked to human feces that ...
Cached Biology News:Popular autism diet does not demonstrate behavioral improvement 2Popular autism diet does not demonstrate behavioral improvement 3UT study finds viruses in untreated East Tennessee drinking water 2
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Prostaglandin-E2 receptor EP2/EP3 Market Segment: GPCRs...
... to BRF2 Immunogen Synthetic peptide: QAARQAATSVPNPP, ... Human BRF2. Reactivity / Specificity Cross-reacts ... Background Information BRF2 is one of ... transcription factor complex required for transcription of genes ...
... Antibody - Red, 20X ... antibody at 20X concentration for use ... assays. Quality Assurance ... FarRed fluorescence polarization assays. ...
Biology Products: